Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | LRRK2 | Q5S007 | 13/20 | 0.38 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.38 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.38 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.37 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30610259 | 1.00 | MAPK1 (0.42) | MAPK1LRRK2MAPK8MAPK9RPS6KB1 | |
| SCHEMBL12411093 | 0.80 | SCD (0.37) | LRRK2GRM5 | |
| SCHEMBL12411098 | 0.79 | CXCR2 (0.33) | LRRK2GRM5 | |
| SCHEMBL15360306 | 0.79 | MAP2K3 (0.39) | RPS6KB1GRM5ADORA2AADORA1 | |
| SCHEMBL15110276 | 0.74 | ALDH1A1 (0.59) | MAPK8MAPK9RPS6KB1JAK2 | |
| SCHEMBL4779779 | 0.74 | LRRK2 (0.48) | LRRK2 | |
| SCHEMBL2492969 | 0.72 | TSHR (0.48) | GRM5ADORA2AADORA1 | |
| SCHEMBL3822146 | 0.71 | KDM4E (0.39) | ADORA2AJAK2 | |
| SCHEMBL28119175 | 0.71 | ADORA3 (0.36) | RPS6KB1ADORA2AADORA1 | |
| SCHEMBL31046830 | 0.71 | ADORA3 (0.36) | RPS6KB1ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104080769-B | Aryl or heteroaryl substituted benzene compounds | EPIZYME股份有限公司 | 2017-06-20 | — | — | CN | disclosed |
| US-20130289013-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS | SUNOVION PHARMACEUTICALS INC. | 2013-10-31 | — | — | US | disclosed |
| US-20110166146-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS | SUNOVION PHARMACEUTICALS INC. (US) | 2011-07-07 | — | — | US | disclosed |
| US-20110166146-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS | SUNOVION PHARMACEUTICALS INC. (US) | 2011-07-07 | — | — | US | disclosed |
| WO-2009143156-A2 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS | SEPRACOR INC. (US) | 2009-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166146-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS | PAICS, ITPA, DPYD | MAPK1 4058/4885LRRK2 4215/4885MAPK8 3503/4885 |
| US-20130289013-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS | PAICS, ITPA, DPYD | MAPK1 4058/4885LRRK2 4215/4885MAPK8 3503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.